Clinical Trials Logo
  1. Home
  2. Ocular Melanoma
  3. NCT01728051

Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver

Cutaneous Melanoma Clinical Trial

Official title:
An Open Label, Expanded Access Study of Melphalan Chemosaturation With the Delcath System in Patients With Ocular and Cutaneous Melanoma Metastatic to the Liver

Clinical Trial Summary

The safety and efficacy of CS-PHP-melphalan has been evaluated in a phase 3 trial conducted in the same patient population as well as using the same melphalan dosing as proposed in this study. This expanded access protocol will provide an experimental alternative treatment option for both physicians and patients until the Delcath CS-PHP System receives marketing approval.

Clinical Trial Description

n/a

Study Design

N/A

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01728051
Study type Expanded Access
Source Delcath Systems Inc.
Contact
Status No longer available
Phase N/A
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Terminated NCT04042480 - A Study of SGN-CD228A in Advanced Solid Tumors Phase 1
Recruiting NCT04020809 - Neoadjuvant Atezolizumab in Cutaneous Melanoma Phase 1
Completed NCT03620019 - Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma Phase 2
Recruiting NCT03767348 - Study of RP1 Monotherapy and RP1 in Combination With Nivolumab Phase 2
Completed NCT03628417 - Confirmatory Trial in the Evaluation of Ca Electroporation for the Treatment of Cutaneous Metastases N/A
Withdrawn NCT05482074 - Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 Phase 2
Recruiting NCT05970497 - A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT04551352 - A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas Phase 1
Recruiting NCT05544929 - A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers Phase 1
Recruiting NCT05628883 - Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma Phase 1
Terminated NCT04254107 - A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer Phase 1
Recruiting NCT04830124 - Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6 Phase 2
Recruiting NCT03699995 - MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma N/A
Recruiting NCT05253872 - The MELAcare Study: A New Method for Surveillance of Melanoma Patients N/A
Recruiting NCT04706962 - TH1902 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04792463 - Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Completed NCT00679289 - Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma Phase 2
Recruiting NCT05669430 - A Study of GV20-0251 in Patients With Solid Tumor Malignancies Phase 1
Recruiting NCT04702854 - Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma N/A